Infliximab Dosing Patterns in a Sample of Patients with Crohn’s Disease: Results from a Medical Chart Review
Joseph Tkacz, MS, Jennifer H. Lofland, PharmD, MPH, PhD, Julie Vanderpoel, PharmD, MPA, Charles Ruetsch, PhD
Crohn’s disease is a chronic relapsing form of inflammatory bowel disease and is characterized by inflammation of the gastrointestinal tract. It is estimated that 1.4 million persons in the United States and 2.2 million persons in Europe have inflammatory bowel disease. The most recent and advanced approach to the treatment of Crohn’s disease is biologic therapy designed to neutralize the proinflammatory effects of the cytokine tumor necrosis factor (TNF)-alpha.
Infliximab Dosing for Crohn’s Disease: Too Much of a Good Thing?
Christopher M. Blanchette, PhD, MBA, Nicholas J. Gross, MD, PhD, Pablo Altman, MD, MBA, F. Randy Vogenberg, RPh, PhD
The clinical and economic burden of chronic obstructive pulmonary disease (COPD) is significant and is increasing. COPD is now the third leading cause of death in the United States, after heart disease and cancer. COPD reached this rank in 2008, more than a decade earlier than projected by the Global Burden of Disease Study. In the United States, mortality due to COPD is the only one among the 5 leading causes of death that showed an increasing rate between 2010 and 2011.
Chronic Obstructive Pulmonary Disease Remains a Growing Population Health Concern
The Internet age has afforded anyone with a cell phone, laptop, or other electronic device access to more information than most people are able to manage comfortably. Conversely, those devices, which are such an indispensable part of modern life, also provide unprecedented, ongoing access to countless pieces of personal information.
Andrea DeVries, PhD, Jinan Liu, PhD, Alexander P. Ruggieri, MD, MHS, Judith J. Stephenson, SM, Gosia Sylwestrzak, MA
The use of anti–tumor necrosis factor (TNF) medications for the treatment of chronic inflammatory conditions, such as rheumatoid arthritis (RA), Crohn’s disease, or psoriasis, represents a large and growing healthcare expenditure. For example, a 2013 sales forecast for adalimumab, the most frequently used injectable anti-TNF, projected continued growth in annual sales from $9.2 billion to $11.2 billion in 2016, and infliximab, an intravenous (IV) infusion anti-TNF, generated more than $7 billion in revenue in 2012.
In a Fix on Addressing Alternatives
Results 1 - 4 of 4